FEops, a Gent, Belgium-based developer of personalized computer modeling for structural heart interventions, secured €6m in Series B funding.
The round was led by Valiance, with participation from existing investors Capricorn and PMV.
The company intends to use the funds to accelerate its product roadmap, centered around FEops HEARTguideTM, and drive commercial adoption in the market for transcatheter valve therapies.
Led by Matthieu De Beule, Ph.D., co-Founder and CEO, FEops has developed a proprietary system to improve transcatheter valve procedures based on personalized computer simulations. Its first product, TAVIguide™, is currently the only CE-marked technology on the market that predicts how a TAVI implant will interact with the patient-specific aortic anatomy and thus provide clinically meaningful insights in the personalized device size selection and position.